SightMD is excited to announce two major milestones in glaucoma treatment. Dr. Alanna Nattis is recognized as one of the first ophthalmologists in the United States to perform the iDose procedure during its FDA clinical trials, while Dr. Eric Rosenberg is the first on Long Island to utilize the now commercially available product.
HAUPPAUGE, N.Y., Oct. 11, 2024 /PRNewswire-PRWeb/ -- SightMD is excited to announce two major milestones in glaucoma treatment. Dr. Alanna Nattis is recognized as one of the first ophthalmologists in the United States to perform the iDose procedure during its FDA clinical trials, while Dr. Eric Rosenberg is the first on Long Island to utilize the now commercially available product.
The iDose is a revolutionary, implantable device designed to continuously release medication inside the eye, providing long-term control of intraocular pressure (IOP) for glaucoma patients. This breakthrough treatment minimizes the need for daily eye drops, offering a more convenient and effective solution for patients who struggle with traditional medication adherence.
"We are proud of both Dr. Nattis and Dr. Rosenberg for their contributions to the advancement of glaucoma care," said Jeffrey Martin, MD, CEO of SightMD. "Dr. Nattis was instrumental in bringing this cutting-edge treatment to the forefront through her work in the clinical trials, and Dr. Rosenberg continues to lead the way by making this life-changing technology available to patients in Long Island."
Dr. Alanna Nattis played a key role in the FDA clinical trials for iDose, positioning her at the forefront of ophthalmic innovation in glaucoma care. Her early involvement has contributed to bringing this technology to market and has had a lasting impact on the future of glaucoma treatment in the U.S.
"It was an incredible opportunity to be involved in the clinical trials for iDose," said Dr. Nattis. "This device has the potential to significantly change the way we manage glaucoma by providing consistent, long-term pressure control without the burden of daily medications."
Dr. Eric Rosenberg, another leader at SightMD, is the first on Long Island to perform the iDose procedure using the commercially available product. His dedication to adopting the latest ophthalmic technologies ensures that Long Island residents have access to the most advanced glaucoma treatments available today.
"Having the iDose as a commercial option is a game-changer for our patients," said Dr. Rosenberg. "It's an honor to be one of the first on Long Island to offer this innovative treatment, and I look forward to improving the quality of life for our glaucoma patients."
SightMD's commitment to advancing eye care technology reflects its mission to provide world-class treatment options that improve outcomes and patient experiences. The introduction of iDose is a major step forward in the management of glaucoma, offering a lasting solution for patients across the region.
For more information or to schedule a consultation with Dr. Nattis or Dr. Rosenberg, visit http://www.sightmd.com or call 855.295.4144.
About SightMD
SightMD is a rapidly-growing integrated ophthalmic group, offering patients access to over 80 doctors through the convenience of 40 locations across New York. SightMD's track record of providing clinically-excellent care spans over 50 years, and its services include LASIK laser vision correction, laser cataract surgery and lens implantation, oculoplastic surgery, general eye exams, glaucoma management, retinal disorder treatment, corneal services, neuro-ophthalmology, pediatric ophthalmology, and audiology. Sight Growth Partners is the administrative services provider for SightMD as well as SightMD Connecticut, SightMD New Jersey, and SightMD Pennsylvania. For more information about SightMD, please visit sightmd.com
Media Contact
Stephanie Penza, SightGrowthPartners, 6318352613, [email protected], www.sightmd.com
SOURCE SightMD
Share this article